The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Christopher W. Ryan

Oregon Health and Science University Knight Cancer Institute

Portland

OR 97239

USA

[email]@ohsu.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA. 2007 - 2011
  • Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, USA. 2005 - 2008
  • Section of Hematology/Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, USA. 2004

References

  1. A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. Ryan, C.W., Vuky, J., Chan, J.S., Chen, Z., Beer, T.M., Nauman, D. Invest. New. Drugs (2011) [Pubmed]
  2. Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. Ryan, C.W., Montag, A.G., Hosenpud, J.R., Samuels, B., Hayden, J.B., Hung, A.Y., Mansoor, A., Peabody, T.D., Mundt, A.J., Undevia, S. Cancer (2008) [Pubmed]
  3. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Ryan, C.W., Huo, D., Stallings, J.W., Davis, R.L., Beer, T.M., McWhorter, L.T. Urology (2007) [Pubmed]
  4. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. Ryan, C.W., Huo, D., Bylow, K., Demers, L.M., Stadler, W.M., Henderson, T.O., Vogelzang, N.J. BJU Int. (2007) [Pubmed]
  5. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Ryan, C.W., Dolan, M.E., Brockstein, B.B., McLendon, R., Delaney, S.M., Samuels, B.L., Agamah, E.S., Vokes, E.E. Cancer Chemother. Pharmacol. (2006) [Pubmed]
  6. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. Ryan, C.W., Huo, D., Demers, L.M., Beer, T.M., Lacerna, L.V. J. Urol. (2006) [Pubmed]
  7. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer. Ryan, C.W., Stadler, W.M., Vogelzang, N.J. BJU Int. (2005) [Pubmed]
  8. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Ryan, C.W., Vogelzang, N.J., Vokes, E.E., Kindler, H.L., Undevia, S.D., Humerickhouse, R., André, A.K., Wang, Q., Carr, R.A., Ratain, M.J. Clin. Cancer Res. (2004) [Pubmed]
 
WikiGenes - Universities